Newsroom

Download PDF – Tivozanib Significantly Improves PFS and ORR Compared to Sorafenib and Demonstrates Updated Interim OS HR of 0.99 in Refractory Advanced RCC – – Outcomes Favor Tivozanib in Patients Previously Treated With Checkpoint Inhibitors as Well as Two VEGFR-TKIs – – Data Featured in Oral Presentation at the 18th International Kidney Cancer Symposium – CAMBRIDGE,

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 12, 2019– AVEO Oncology (NASDAQ: AVEO) today reported financial results for the third quarter ended September 30, 2019 and provided a business update. “This quarter we have made meaningful progress toward our goal of bringing effective and better tolerated therapies to patients battling kidney and other cancers,” said Michael Bailey, president and chief executive officer of AVEO.

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 7, 2019– AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced the initiation of the CyFi-2 study, a randomized Phase 2 clinical study evaluating ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory antibody product candidate, in combination with high-dose cytarabine vs. high-dose cytarabine alone in patients with relapsed and refractory acute myeloid leukemia (AML). AVEO will

Download PDF – NDA Filing Planned for 1Q20 for Relapsed/Refractory RCC – – Company Plans Final OS Analysis in 2Q20 – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 4, 2019– AVEO Oncology (NASDAQ: AVEO) today provided a regulatory update following a meeting with the U.S. Food and Drug Administration (FDA) to discuss results from the August 2019 overall survival (OS) analysis of the TIVO-3 trial and the

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 30, 2019– AVEO Oncology (NASDAQ: AVEO) today announced that it has initiated enrollment in an open-label, multi-center Phase 1b/2 clinical trial evaluating FOTIVDA® (tivozanib), the Company’s once-daily, potent and selective vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), in combination with IMFINZI® (durvalumab), AstraZeneca’s human monoclonal antibody directed against programmed death-ligand 1 (PD-L1), in

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 26, 2019– AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 2019 Cantor Fitzgerald Global Healthcare Conference in New York on Friday, October 4, 2019 at 10:05 a.m. Eastern Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of

Download PDF – Results Suggest Additive or Synergistic Activity in Both Treatment Naïve and Previously Treated Patients –    -Tivozanib-Nivolumab Combination Generally Well Tolerated –   – Data to be Presented at the ESMO 2019 Annual Congress –   CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 23, 2019– AVEO Oncology (NASDAQ: AVEO) and EUSA Pharma today announced the upcoming presentation of final results from the

Download PDF – 20 Patients Remain Progression Free on Tivozanib Arm vs. 2 on Sorafenib Arm – – Company Plans to Discuss Updated Results with FDA – – AVEO to Host Conference Call Today at 8:00 am Eastern Time – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 10, 2019– AVEO Oncology (NASDAQ: AVEO) today announced results from the second prespecified analysis of overall survival (OS) in the TIVO-3 trial. TIVO-3